Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kamada Ltd KMDA

Healthcare Biotechnology
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune... see more

Recent & Breaking News (NDAQ:KMDA)

Kamada to Present at the Jefferies Global Plasma Summit

GlobeNewswire March 9, 2021

Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.

GlobeNewswire March 3, 2021

Kamada Files Annual Report for the Year Ended December 31, 2020

GlobeNewswire February 24, 2021

Kamada Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development Activities

GlobeNewswire February 10, 2021

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2020 Financial Results, and Host Conference Call on February 10, 2021

GlobeNewswire February 3, 2021

Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA

GlobeNewswire February 1, 2021

Kamada Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel

GlobeNewswire January 13, 2021

Kamada Selected as a Winner of the Genesis Prize Foundation and Start-Up Nation Central Competition

GlobeNewswire January 5, 2021

Kamada Added to the NASDAQ Biotechnology Index

GlobeNewswire December 21, 2020

Kamada Reports Third Quarter and First Nine Months of 2020 Financial Results, Recent Achievements and Corporate Development

GlobeNewswire November 11, 2020

Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020

GlobeNewswire November 4, 2020

Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021

GlobeNewswire October 19, 2020

Kamada Provides Update on 2021 GLASSIA® Supply to Takeda

GlobeNewswire October 7, 2020

Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)

GlobeNewswire September 8, 2020

Kamada Announces Changes to its Board of Directors

GlobeNewswire August 12, 2020

Kamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position

GlobeNewswire August 12, 2020

Kamada Announces Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel

GlobeNewswire August 10, 2020

Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020

GlobeNewswire August 5, 2020

Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel

GlobeNewswire June 17, 2020

Kamada Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Progress

GlobeNewswire May 18, 2020